Discovery of indoleninyl-pyrazolo[3,4-b]pyridines as potent chemotherapeutic agents against colorectal cancer cells
- PMID: 38460334
- DOI: 10.1016/j.bioorg.2024.107256
Discovery of indoleninyl-pyrazolo[3,4-b]pyridines as potent chemotherapeutic agents against colorectal cancer cells
Abstract
A new series of indolenines decorated with pyrazolo[3,4-b]pyridines were designed and synthesized in up to 96% yield from the acid-catalyzed cyclocondensation of 1,3-dialdehydes with 3-aminopyrazoles. X-ray crystallography on a representative derivative, 5n, revealed two close to planar conformations whereby the N-atom of the pyridyl residue was syn or anti to the pyrrole-N atom in the two independent molecules of the asymmetric unit. The computational and DNA binding data suggest that 5n is a strong DNA intercalator with the results in agreement with its potent cytotoxicity against two colorectal cancer cell lines (HCT 116 and HT-29). In contrast to doxorubicin, compounds 5k-o have higher druggability (compliance to more criteria stated in Lipinski's rule of five and Veber's rule), higher bioavailability, and better medicinal chemistry properties, indicative of their potential application as chemotherapeutical agents.
Keywords: Cytotoxicity; DNA binding; Indolenines; Pyrazolo[3,4-b]pyridines; X-ray crystallography.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Design, synthesis, molecular modeling and biological evaluation of novel 1H-pyrazolo[3,4-b]pyridine derivatives as potential anticancer agents.Bioorg Chem. 2016 Aug;67:43-56. doi: 10.1016/j.bioorg.2016.05.006. Epub 2016 May 20. Bioorg Chem. 2016. PMID: 27253830
-
Synthesis, anticancer assessment on human breast, liver and colon carcinoma cell lines and molecular modeling study using novel pyrazolo[4,3-c]pyridine derivatives.Bioorg Chem. 2018 Apr;77:203-214. doi: 10.1016/j.bioorg.2017.12.032. Epub 2018 Jan 10. Bioorg Chem. 2018. PMID: 29367077
-
Synthesis and anti-tumor activities of some new pyridines and pyrazolo[1,5-a]pyrimidines.Eur J Med Chem. 2009 Sep;44(9):3519-23. doi: 10.1016/j.ejmech.2009.03.042. Epub 2009 Apr 8. Eur J Med Chem. 2009. PMID: 19398146
-
One-pot three-component synthesis of novel pyrazolo[3,4-b]pyridines as potent antileukemic agents.Eur J Med Chem. 2022 Jan 5;227:113952. doi: 10.1016/j.ejmech.2021.113952. Epub 2021 Oct 29. Eur J Med Chem. 2022. PMID: 34731763
-
Synthesis and biological evaluation of novel pyrazolo[3,4-b]pyridines as cis-restricted combretastatin A-4 analogues.Bioorg Med Chem Lett. 2020 Apr 15;30(8):127025. doi: 10.1016/j.bmcl.2020.127025. Epub 2020 Feb 11. Bioorg Med Chem Lett. 2020. PMID: 32063430
Cited by
-
Bioactive Fused Pyrazoles Inspired by the Adaptability of 5-Aminopyrazole Derivatives: Recent Review.Molecules. 2025 Jan 17;30(2):366. doi: 10.3390/molecules30020366. Molecules. 2025. PMID: 39860235 Free PMC article. Review.
-
Synthesis and Neurotropic Activity of New 5-Piperazinopyrazolo[3,4-c]-2,7-naphthyridines and Isoxazolo[5,4-c]-2,7-naphthyridines.Pharmaceuticals (Basel). 2025 Apr 19;18(4):597. doi: 10.3390/ph18040597. Pharmaceuticals (Basel). 2025. PMID: 40284032 Free PMC article.
-
Computational Elucidation of Hub Genes and Pathways Correlated with the Development of 5-Fluorouracil Resistance in HCT 116 Colorectal Carcinoma Cell Line.Biochem Genet. 2025 Jan 30. doi: 10.1007/s10528-025-11041-2. Online ahead of print. Biochem Genet. 2025. PMID: 39883358
-
Integrative Network Pharmacology and Molecular Docking Analyses on the Mechanisms of San-Zhong-Kui-Jian-Tang in Treating Oral Squamous Cell Carcinoma.Curr Med Sci. 2025 Aug;45(4):755-774. doi: 10.1007/s11596-025-00067-7. Epub 2025 Jun 17. Curr Med Sci. 2025. PMID: 40526272
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous